Position of the Transparency Council – Oxervate (cenegermin)

At its meeting on 9 December 2024, the Transparency Council adopted position No. 143/2024 on the appropriateness of issuing approvals for reimbursement of the drug Oxervate (cenegermin) for the indication: neurotrophic keratitis in adults

Publication of the position >>